Abstract:Wendy B. London 1 , Hannah Bousquet 1 , Meredith S. Irwin 2 , Michael D. Hogarty 3 , Susan L. Cohn 4 1 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Division of Hematology/Oncology, Department of Pediatrics, Harvard Medical School, Boston, MA, USA; 2 Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 3 Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 4 Department of Pediatrics and Comer Children's Hospital, University of Chicago, Chicago, IL, USA Response to: Pérez-García MJ, Segura MF. Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients. Transl Pediatr 2023;12:1926-30. Erratum in: Transl Pediatr 2024;13:1514. Submitted Aug 19, 2024. Accepted for publication Oct 09, 2024. Published online Oct 28, 2024. doi: 10.21037/tp-24-319 We thank the authors for their supportive comments on our manuscript about the revision to the Children's Oncology Group (COG) neuroblastoma risk stratification based on a change in age cut-off from 12 to 18 months (1,2). The authors have provided a well-described and helpful overview of the application of biomarkers to risk stratify patients, as well as describing treatment and late effects. They have nicely summarized the comparative evidence of our successful reduction of therapy due to the described COG risk stratification changes. In addition to the change in age cut-off, COG risk stratification is anticipated to improve by using the INRGSS (International Neuroblastoma Risk Group Staging System) (3) instead of INSS (International Neuroblastoma Staging System) (4,5). INSS was utilized in 2006 when the change in age cut-off was made, but has since been replaced by the INRGSS in the COG neuroblastoma risk classifier version 2. INRGSS is a pre-surgical staging system which quantifies the disease extent at diagnosis, compared to INSS, which is post-surgical and dependent on surgical discretion. The authors describe the use of the International Neuroblastoma Pathology Classification (INPC) as a biomarker in COG risk stratification. Age is one of the factors used to classify tumors as INPC favorable or unfavorable. In the context of risk stratification, using both age and INPC leads to a duplication of the prognostic contribution of age, i.e., confounding. Further improvements in risk stratification should utilize the underlying components of INPC [histologic category, mitosis-karyorrhexis index (MKI), and grade of differentiation] as separate risk factors, to eliminate this problematic confounding (6). We thank the authors for describing the LEAHRN (Late Effects After High-Risk Neuroblastoma) study, the first comprehensive study specifically focused on late effects in survivors of high-risk neuroblastoma (7). These survivors were diagnosed on/after January 1, 2000, with a minimum of 5 years follow-up after diagnosis. The authors state that survivors were treated between 2000–2006; however, many LEAHRN patients were treated after 2006 with more contemporary therapy. The authors state that " While this re-classification saved children to be exposed to unnecessary treatments, their outcome should remain unaltered ". Certainly, it was our hope that their outcome remains 'unaltered', but we should clarify our intent. We hypothesized that despite receiving less intensive therapy, these groups would maintain the same outstanding survival outcomes as they had when they received high-risk therapy, albeit with fewer late effects. Fortunately, we were able to present evidence supporting that hypothesis. We agree with the authors that it is a limitation of our study that only 20 of the 105 patients received treatment through enrollment on clinical trials, and actual treatment received is unknown for most. However, there is anecdotal evidence that most patients in North America who are not enrolled on a COG clinical trial are treated "as per" the clinical trial, receiving the standard-of-care intermediate-risk or high-risk treatment according to the COG risk stratification (8). We agree with the authors that international data harmonization and novel molecular biomarkers will be critically important to further optimize risk stratification and outcomes (9). We only identified 105 patients enrolled over 30 years in our cohort of interest, highlighting the importance of international collaborations and shared data to better characterize and classify rare subgroups. Furthermore, until such time as predictive biomarkers and drugs for targeted therapy are available for neuroblastoma, research on improved prognostic stratification should continue, as one means to con -Abstract Truncated-

Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial

Improvements in Children's Oncology Group neuroblastoma risk stratification through a change in age cut-off and use of INRGSS

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Response-adapted consolidation therapy strategy for patients with metastatic high-risk neuroblastoma: Results of the SMC NB-2014 study

A nationwide phase II study of delayed local treatment for children with high‐risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN‐H‐11

Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531

Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer

[Short-term results of a multicenter study based on a modified N7 induction regimen combined with arsenic trioxide in the treatment of children with high-risk neuroblastoma]

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994

Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.

Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial

Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results from a Prospective Clinical Trial

Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A network meta-analysis (NMA) with matching-adjusted indirect comparison (MAIC).